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Abstract	
	
Background	
Despite	increasing	evidence	supporting	the	clinical	utility	of	immune	infiltration	in	the	estrogen	
receptor-negative	(ER-)	subtype,	the	prognostic	value	of	immune	infiltration	for	ER+	disease	is	
not	well	defined.			
Methods	
Quantitative	immune	scores	of	cell	abundance	and	spatial	heterogeneity	were	computed	using	
fully	 automated	hematoxylin	&	eosin-stain	 image	analysis	 algorithm	and	 spatial	 statistics	 for	
1,178	 postmenopausal	 patients	 with	 ER+	 breast	 cancer	 treated	 with	 5	 years’	 tamoxifen	 or	
anastrozole.	 Prognostic	 significance	 of	 immune	 scores	was	 compared	with	Oncotype	DX	 21-
gene	recurrence	score	(RS),	PAM50	risk	of	recurrence	(ROR)	score,	IHC4,	and	clinical	treatment	
score	(CTS)	available	for	963	patients.		
Results	
Scores	 of	 immune	 cell	 abundance	 were	 not	 associated	 with	 recurrence-free	 survival.	 In	
contrast,	 high	 immune	 spatial	 scores	 indicating	 increased	 cell	 spatial	 clustering	 were	
associated	 with	 poor	 10-year,	 early	 (0-5	 year)	 and	 late	 (5-10	 year)	 recurrence-free	 survival	
(Immune	Hotspot	LR-χ2	=	14.06,	P	<	0.001	for	0-10	year;	LR-χ2	=	6.24,	P	=	0.01	for	0-5	year;	LR-χ2	
=	7.89,	P	=	0.005	for	5-10	year).	The	prognostic	value	of	spatial	scores	for	late	recurrence	was	
similar	 to	 that	 of	 IHC4	 and	 RS	 in	 both	 populations,	 but	 was	 not	 as	 strong	 as	 other	 tests	 in	
comparison	for	recurrence	across	10	years.		
Conclusions	
These	 results	 provide	 a	 missing	 link	 between	 tumor	 immunity	 and	 disease	 outcome	 in	 ER+	
disease	by	examining	 tumor	 spatial	 architecture.	The	association	between	spatial	 scores	and	
late	recurrence	suggests	a	lasting	memory	of	pro-tumor	immunity	that	may	impact	on	disease	
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progression	 and	 evolution	 of	 endocrine	 treatment	 resistance,	 which	 may	 be	 exploited	 for	
therapeutic	advances.		
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Introduction	
Estrogen	receptor-positive	(ER+)	subtype	accounts	for	about	80%	of	all	breast	cancers,	
the	most	 common	cancer	 in	women.	At	diagnosis,	 the	majority	of	ER+	patients	have	a	good	
prognosis	if	treated	with	endocrine	therapy.	However,	a	subset	of	patients	is	at	risk	for	disease	
recurrence	and	death,	particularly	after	5	years	of	adjuvant	endocrine	therapy.	Differentiating	
these	 patients	 from	 low-risk	 patients	 who	 can	 safely	 avoid	 chemotherapy	 is	 a	 priority	 for	
breast	 cancer	 management	 (1).	 Currently	 available	 prognostic	 tests	 to	 predict	 risk	 in	
endocrine-treated	 patients	 include	 the	 widely	 used	 Oncotype	 DX	 21-gene	 recurrence	 score	
(RS)	 (2),	 the	PAM50	risk	of	recurrence	(ROR)	score	(3),	and	the	 immunohistochemistry-based	
IHC4	 test	 that	 is	 combined	 with	 the	 clinical	 treatment	 score	 (CTS)	 to	 integrate	
clinicopathological	 parameters	 (4).	 In	 particular,	 the	 amount	 of	 prognostic	 information	
provided	for	long-term	(0-10	years)	and	late	(beyond	five	years)	recurrence	varies	across	these	
tests	(5,	6).		
Immune	 infiltration	 is	 not	 explicitly	 accounted	 for	 in	 any	 of	 the	 above	 tests.	
Increasing	 evidence	 supports	 the	 role	 of	 tumor-infiltrating	 lymphocytes	 (TILs)	 in	 influencing	
disease	progression	and	 treatment	 response	 in	breast	 cancer	 (7-10). Characterization	of	 the	
nature	 of	 immune	 responses	 is	 key	 to	 understanding	 tumor	 immunity	 and	 empowering	
immunotherapy.		However,	the	majority	of	reports	focus	on	ER-	and	Human	Epidermal	growth	
factor	receptor	2-positive	(HER2+)	breast	cancers,	where	extensive	immune	infiltration	is	more	
common	and	 immune	 scores	were	 found	 to	be	highly	predictive	of	 survival	 and	 response	 to	
chemotherapy	(8,	11-15).	In	contrast,	there	is	a	lack	of	definitive	data	on	the	prognostic	value	
of	immune	scores	in	ER+	breast	cancer	following	endocrine	treatment	(7,	16).	A	major	reason	
for	this	is	the	absence	of	reproducible	scoring	methods	to	facilitate	large-scale	studies	of	ER+	
breast	cancer.	This	also	limits	the	translation	of	immune	scoring	into	clinical	advances.	
We	 have	 developed	 quantitative	 and	 reproducible	 approaches	 to	 score	 lymphocytic	
infiltration	 (LI)	 in	 breast	 cancer,	 based	 on	 fully	 automated	 image	 analysis	 of	 routinely	
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generated	hematoxylin	&	eosin	(H&E)-stained	histology	sections.	Quantitative	immune	scores	
of	 overall	 LI	 in	 tumors,	 as	well	 as	 intra-tumor	 lymphocyte	 ratio	 (ITLR),	were	 associated	with	
good	survival	 in	ER-	and	ER-/HER2-	breast	cancer	 (17,	18).	 In	addition,	our	automated	 image	
analysis	 scheme	 enables	 the	 study	 of	 complex	 spatial	 patterns	 of	 TILs	 (19).	 The	 spatial	
interactions	 among	 TILs	 and	 cancer	 cells	 generate	 complex	 ecological	 dynamics	 that	 can	
ultimately	 impact	 tumor	 progression	 and	 response	 to	 treatment	 (8,	 20-22).	 In	 this	 study	 of	
1,178	postmenopausal	breast	cancer	patients	with	ER+	disease	patients	enrolled	 in	the	ATAC	
(Arimidex	or	Tamoxifen	Alone	or	Combined)	trial,	our	aims	were	to:	1)	establish	the	prognostic	
value	of	H&E-based,	quantitative	scores	of	TIL	abundance	as	well	as	spatial	heterogeneity	for	
10-year,	early	(0-5	year)	and	late	(5-10	year)	recurrence	after	endocrine	therapy;	2)	compare	
their	 prognostic	 value	with	 established	 prognostic	 tests	 including	 RS,	 ROR,	 IHC4	 and	 CTS;	 3)	
evaluate	 a	 new	 histology-based	 model	 that	 combines	 IHC4	 and	 immune	 scores	 as	 a	 cost-
effective	biomarker.	
	
	
Materials	and	Methods		
Study	population	
Classical	 clinicopathologic	 factors	 (age,	 nodal	 status,	 tumor	 size,	 grade,	 randomized	
treatment)	were	collected	from	patients	with	ER+	primary	breast	cancer	in	the	ATAC	trial	who	
were	 randomly	 assigned	 to	 either	 anastrozole	 or	 tamoxifen	 (23)	 (Supplementary	 Table	 1).	
1,178	eligible	patients	who	did	not	receive	chemotherapy	and	from	whom	H&E-stained	slides	
from	 formalin-fixed,	 paraffin-embedded	 tissues	 were	 available	 were	 included	 (Figure	 1).	 Of	
these,	 963	 patients	 were	 scored	 with	 prognostic	 scores	 including	 IHC4,	 RS,	 ROR46	 and	 CTS	
(Table	 1).	 1,037	 tumors	 were	 HER2-,	 909	 of	 which	 were	 scored	 with	 prognostic	 scores.	 A	
subset	 of	 91	 TransATAC	 samples	 were	 randomly	 selected	 and	 scored	 on	 H&E	 sections	
according	 to	 international	 recommendations	 (24)	 by	 a	 histopathologist	 (KN).	 Baseline	
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demographics	and	clinical	characteristics	for	all	patients	included	in	this	analysis	are	provided	
in	Supplementary	Table	1. This	study	was	approved	by	the	South-East	London	Research	Ethics	
Committee,	and	all	patients	included	gave	informed	consent.		
	
H&E	image	analysis	and	validation	
We	curated	a	digital	database	of	H&E	histology	slides	 for	TransATAC	and	applied	our	
histology	image	analysis	pipeline	(17)	(Supplementary	Figure	1A).	 In	brief,	the	image	analysis	
pipeline	exploits	the	nuclear	morphological	differences	among	cancer	cells,	 lymphocytes,	and	
stromal	 cells	 to	 differentiate	 them	 in	H&E	 histological	 tissue	 sections.	 Cancer	 cell	 nuclei	 are	
generally	 large	 in	 size	 and	 demonstrate	 greater	 variability	 in	 appearance	 as	 compared	 to	
lymphocyte	 and	 stromal	 cell	 nuclei;	 lymphocyte	 nuclei	 are	 typically	 small,	 round	 and	
homogeneously	 basophilic,	 and	 nuclei	 of	 stromal	 cells	 including	 fibroblasts	 and	 endothelial	
cells	are	more	elongated.	The	pipeline	consisted	of	four	stages:	(1)	unsupervised	segmentation	
of	 the	 nuclei;	 (2)	 supervised	 classification	 of	 individual	 cell	 nuclei	 into	 cancer,	 lymphocyte,	
other	cell	nuclei,	and	artefacts;	(3)	kernel	smoothing	to	correct	local	sporadic	errors;	and	(4)	a	
hierarchical	multi-resolution	model	 fitting	 to	 identify	 cancer	 cell	 clusters	 to	 further	 improve	
classification	accuracy.	The	classifier	was	previously	validated	in	METABRIC	to	have	an	overall	
accuracy	of	 90.1%	and	a	high	 correlation	 between	 image	 analysis	 and	pathological	 scores	 in	
the	entire	cohort	(17).	
To	evaluate	the	accuracy	of	our	image	analysis	pipeline	for	TransATAC,	a	test	set	of	627	
cells	 randomly	 sampled	 from	 3	 images	 were	 annotated	 by	 a	 pathologist	 (DNR)	 blinded	 to	
image	analysis	results	(Supplementary	Figure	1A).	Accuracy	for	identifying	the	three	cell	types	
was:	cancer	cell	93.8%,	lymphocyte	87.9%	and	stromal	cell	84.2%	(Supplementary	Figure	1B).	
The	 balanced	 accuracy	 as	 the	 average	 for	 sensitivity	 and	 specificity	 for	 the	 three	 cell	 types	
were	0.864	for	cancer,	0.839	for	lymphocyte	and	0.876	for	stromal	cell	(Supplementary	Figure	
1C).	 On	 average	 217,101	 cancer	 cells	 (±178677.5),	 25,956	 lymphocytes	 (±35365.21)	 and	
8		
161,341	 stromal	 cells	 (±91862.59)	were	 identified	 in	 each	 TransATAC	whole-section	 sample,	
with	a	total	of	525,718,198	cells	identified	in	the	whole	cohort.	
	
Automated	scoring	of	immune	cell	abundance	and	spatial	heterogeneity			
Immune	cell	abundance	scores	include	Lymphocytic	Infiltration	(LI)	which	summarizes	
the	 fraction	 of	 lymphocytes	 in	 all	 cells	 in	 the	 tumor	 section,	 Intra-Tumor	 Lymphocyte	 Ratio	
(ITLR),	 Adjacent-to-Tumor	 Lymphocyte	 Ratio	 (ATLR)	 and	 Distal-To-Tumor	 Lymphocyte	 Ratio	
(DTLR)	which	are	defined	as	 the	number	of	 specific	 types	of	 lymphocytes	normalized	by	 the	
number	 of	 cancer	 cells	 (17,	 18).	 Intra-Tumor	 Lymphocytes	 (ITLs),	 Adjacent-to-Tumor	
Lymphocytes	 (ATLs)	 and	 Distal-To-Tumor	 Lymphocytes	 (DTLs)	 were	 identified	 using	
unsupervised	clustering	based	on	their	spatial	proximities	to	cancer	cells,	which	was	quantified	
using	a	kernel	density	method	on	the	distribution	of	cancer	cells.		
Immune	cell	spatial	scores	quantify	the	amount	of	spatial	clusters,	or	hotspots,	formed	
by	lymphocytes	and/or	cancer	cells	within	the	section	(Figure	2)	(13).	Getis-Ord	spatial	analysis	
was	 carried	 out	 to	 identify	 tumor	 regions	 with	 statistically	 significant	 spatial	 clustering	 of	
immune	 cells,	 i.e.,	 immune	 hotspots. This	 means	 that,	 the	 frequency	 of	 immune	 cells	
appearing	 at	 these	 locations	 is	 greater	 than	expected	by	 chance	given	 the	distribution	of	 all	
cells	in	the	entire	tumor	section	and	that,	importantly,	the	difference	between	the	actual	and	
expected	 value	 is	 statistically	 significant.	 A	 p-value	 was	 computed	 for	 each	 spatial	 region,	
which	 can	 be	 used	 to	 determine	 statistical	 significance	 using	 a	 significance	 level	 of	 0.05.	
Previously,	tumors	with	a	high	amount	of	regions	that	are	both	immune	hotspots	and	cancer	
hotspots	 (immune-cancer	 hotspots)	 were	 found	 to	 have	 good	 prognosis	 in	 ER-	 cancer	 (13).	
Here	 for	 comparison	 in	 ER+	breast	 cancer,	 Cancer	Hotspot	 and	 Immune	Hotspot	 scores	 that	
examine	only	one	type	of	cell	at	a	time	were	also	included.		
For	 validation	 of	 the	 inter-correlations	 among	 immune	 scores,	 H&E-stained,	 whole-
section	 images	 of	 743	 ER+,	 treatment-naïve	 primary	 tumors	 from	 the	METABRIC	 study	 (25)	
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were	analyzed	using	the	same	methods.	All	patient	specimens	were	obtained	with	appropriate	
ethical	approval	from	the	relevant	institutional	review	boards.		
	
Statistical	analyses	
Our	 primary	 objective	 was	 to	 assess	 whether	 immune	 scores	 had	 statistically	
significant	 prognostic	 information	 for	 predicting	 10-year	 recurrence	 in	 postmenopausal	
women	 with	 breast	 cancer	 given	 either	 tamoxifen	 or	 anastrozole	 monotherapy	 but	 not	
chemotherapy.	 Secondary	 analyses	 included	 determining	 the	 prognostic	 ability	 of	 immune	
scores	 in	predicting	early	 (0-5	year)	and	 late	 recurrences	 (5-10	year),	 in	patients	divided	 into	
subgroups	 by	 HER2	 status,	 and	 the	 additional	 prognostic	 information	 provided	 by	 tests	 in	
multivariable	 comparisons	 including	age	 (<65,	 ≥65	 years),	 nodal	 status	 (0,1-3,4+),	 tumor	 size	
(≤1cm,	 >1	 to	 ≤2cm,	 >2to	 ≤3cm,	 >3	 cm),	 centrally	 read	 grade	 (poor,	 intermediate,	 well	
differentiated),	and	randomized	treatment	(anastrozole	v	tamoxifen).	Hazard	Ratios	are	for	a	
change	 in	 1	 SD	 in	 the	 overall	 dataset	 to	 compare	 the	 effect	 size	 between	different	 immune	
scores.	 The	 contribution	 of	 each	 of	 the	 variables	was	 evaluated	 by	 the	 change	 in	 likelihood	
ratio	 χ2	 (LR-χ2;	 1	 df,	 significance	 level	 χ2=3.84)	 in	 three	 ways:	 by	 univariate	 analyses,	 as	 an	
addition	to	a	model	containing	only	the	clinical	variables,	and	as	a	difference	in	LR-χ2	when	the	
variable	was	added	to	 the	 IHC4	score.	Sample	splitting	was	used	 in	which	 the	 immune	score	
was	 dichotomized	 by	 using	 half	 the	 data	 as	 the	 training	 set,	 and	 then	 the	 cut-off	 points	 for	
each	score	were	evaluated	in	the	remaining	half	of	the	data	as	the	validation	set.	Since	the	use	
of	optimizing	cut-offs	may	lead	to	overestimation	of	prognostic	power,	dichotomized	variables	
were	 only	 used	 for	 analysis	 presented	 in	 Figure	 2B-D,	 and	 continuous	 variables	 were	 used	
elsewhere.	For	measuring	correlation	among	immune	scores	and	with	pathological	TIL	scores,	
Spearman’s	correlation	was	used.	All	statistical	analyses	were	performed	using	STATA	version	
13.1	or	R	version	3.3.1.		All	statistical	tests	were	two-sided	and	a	P	value	of	less	than	0.05	was	
considered	statistically	significant.		
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Results	
Correlations	among	immune	scores	
Four	 immune	 abundance	 scores	 (overall	 Lymphocytic	 Infiltration	 LI,	 Intra-Tumor	
Lymphocyte	 Ratio	 ITLR,	 Adjacent-to-Tumor	 Lymphocyte	 Ratio	 ATLR	 and	 Distal-To-Tumor	
Lymphocyte	Ratio	DTLR)	and	three	spatial	scores	(Immune	Hotspot,	Cancer	Hotspot,	Immune-
Cancer	Hotspot)	were	calculated	based	on	fully	automated	histology	image	analysis	on	whole	
section	 slides	 (Figure	 2,	 Table	 1,	 Supplementary	 Figure	 2).	 There	 was	 a	 strong,	 negative	
correlation	 between	 ITLR	 and	DTLR	 (r	 =	 -0.888,	Table	 2),	 indicating	 that	 lymphocytes	 either	
infiltrate	 into	close	contact	with	cancer	cells,	or	 largely	stay	 in	the	stromal	area.	Correlations	
among	 spatial	 scores	were	also	 strong	 (r	 =	0.502-0.796),	 suggesting	 that	 spatial	 clustering	of	
cancer	cells	and	lymphocytes	tends	to	co-occur	 in	the	same	tumors.	These	data	were	further	
validated	in	the	METABRIC	cohort	(25)	(n	=	743,	Table	2).	We	then	compared	the	automated	
scores	to	a	pathologist’s	TIL	score	 (24)	 in	a	subset	of	91	TransATAC	samples.	Overall,	a	weak	
correlation	between	 the	pathologist’s	 score	and	all	 automated	 scores	was	 found	 (r	 <	0.260),	
with	 the	 highest	 correlation	 observed	 between	 TILs	 scoring	 and	 DTLR	 (r	 =	 0.259)	
(Supplementary	Figure	3).				
	
Prognostic	value	of	immune	scores	
None	of	the	immune	abundance	scores	provided	significant	prognostic	information	for	
recurrence	 (p	 >	 0.1).	 In	 contrast,	 high	 spatial	 scores	were	 associated	with	 significantly	 poor	
recurrence-free	survival	across	10	years	in	the	univariate	analysis	(n	=	1,178,	Immune	Hotspot	
LR-χ2	 =	 14.06,	 P	 <	 0.001;	 Table	 3).	 When	 dichotomized,	 immune	 spatial	 scores	 were	 also	
prognostic	 (Immune	Hotspot	 training	set	n	=	589,	p	=	0.01,	Hazard	Ratio	HR	=	1.88	and	95%	
Confidence	 Interval	CI	=	 [1.16-3.07];	validation	set	n	=	589,	p	=	0.002,	HR	=	2.21	 [1.35-3.63],	
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Figure	 2,	 Supplementary	 Figure	 4).	 In	 addition,	 immune	 spatial	 scores	 were	 significantly	
prognostic	for	early	(0-5	year)	and	late	recurrence	(5-10	year)	(Immune	Hotspot	0-5	year:	LR-χ2	
=	 6.24,	 P	 =	 0.01;	 5-10	 year:	 LR-χ2	 =	 7.89,	 P	 =	 0.005;	 Table	 3).	 In	 the	 multivariate	 analysis	
adjusted	for	clinical	variables	as	expressed	by	the	CTS	including	node	status,	tumor	size,	grade,	
age	and	treatment,	spatial	scores	remained	prognostic	for	all	three	time	windows,	except	for	
Cancer	Hotspot	for	early	recurrence	and	Immune-Cancer	Hotspot	for	late	recurrence	(Table	3).		
None	of	the	patients	in	this	study	received	trastuzumab	if	their	tumors	were	HER2+,	as	
is	current	practice.	In	the	HER2-	population	(n=1,037),	again	spatial	scores	but	not	abundance	
scores	 were	 prognostic	 for	 all	 time	 windows	 (Table	 3).	 In	 the	 multivariate	 analysis,	 spatial	
scores	were	prognostic	for	all	time	windows	except	for	Immune	Hotspot	and	Immune-Cancer	
Hotspot	for	early	recurrence	(Table	3).	We	henceforth	focused	on	spatial	scores	only.		
	
Comparison	of	immune	spatial	scores	with	RS,	IHC4,	ROR,	and	CTS	
The	prognostic	value	of	spatial	scores	for	late	recurrence	(5-10	year)	is	similar	to	that	
of	IHC4	and	RS	in	both	the	overall	population	(Immune	Hotspot:	LR-χ2	=	6.93,	IHC:	LR-χ2	=	6.75,	
RS:	LR-χ2	=	6.79)	and	the	HER2-	population	(Immune	Hotspot	LR-χ2	=	9.80,	IHC4	LR-χ2	=	10.87,	
RS	 LR-χ2	 =	 7.78,	 Figure	 3).	 None	 of	 these	 scores,	 however,	 added	 to	 IHC4	 and	 RS	 for	 early	
recurrence	(∆LR-χ2	≤	3.84)	or	was	as	prognostic	as	ROR	and	CTS	in	any	time	window	(Figure	3).	
We	 then	examined	 the	additional	prognostic	 value	of	 spatial	 scores	 to	 IHC4	and	RS	 for	0-10	
year	and	late	recurrence.	 Immune-Cancer	Hotspot	provided	statistically	significant	prognostic	
value	 when	 added	 to	 IHC4	 and	 RS	 for	 years	 0-10	 whereas	 Immune	 Hotspot	 also	 added	
prognostic	value	to	IHC4	and	RS	for	late	recurrence	(∆LR-χ2	>	3.84,	Table	4).	Cancer	Hotspot,	on	
the	other	hand,	added	prognostic	information	to	IHC4	and	RS	in	both	time	windows	(Table	4).	
In	 the	 HER2-	 population,	 Immune	 Hotspot	 and	 Immune-Cancer	 Hotspot	 added	 statistically	
significant	 prognostic	 information	 to	 IHC4	 and	 RS	 in	 both	 time	 windows	 (Table	 4).	 Again,	
Cancer	Hotspot	added	statistically	significant	information	to	IHC4	and	RS	in	both	time	windows	
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(Table	 4).	 However,	 none	 of	 the	 spatial	 scores	 provide	 significant	 prognostic	 information	
beyond	that	of	CTS	or	ROR	in	the	HER2-	or	the	overall	population	(∆LR-χ2	≤	3.84).	
	
IHC4+Immune	spatial	score	
To	 evaluate	 a	 new	 biomarker	 based	 entirely	 on	 histology	 slides,	 we	 sought	 to	
determine	the	prognostic	value	of	a	combined	model	of	IHC4	and	spatial	scores	for	0-10	year	
and	late	recurrence.	The	prognostic	value	of	IHC4	and	RS	are	similar	in	the	two-time	windows	
and	 populations	 (∆LR-χ2	 ≤	 3.84).	 For	 predicting	 recurrence	 across	 10	 years,	 Cancer	 Hotspot	
combined	 with	 IHC4	 achieved	 a	 better	 performance	 than	 RS	 alone	 in	 both	 cohorts	 (overall	
population	 ∆LR-χ2=	 9.23;	 in	 HER2-:	 ∆LR-χ2	 =	 6.54,	 Figure	 3).	 For	 predicting	 late	 recurrence,	
prognostic	value	higher	than	RS	was	observed	for	IHC4	combined	with	any	of	the	spatial	score	
in	both	populations,	except	 for	 Immune-Cancer	Hotspot	 in	 the	overall	population	 (Figure	 3).	
However,	 none	 of	 the	 combined	 scores	 outperformed	 CTS	 and	 ROR.	 Finally,	 IHC4	 combined	
with	spatial	scores	added	prognostic	value	to	CTS,	similar	to	that	achieved	by	the	RS	but	lower	
than	 ROR	 in	 the	 overall	 population	 (∆LR-χ2:	 IHC4+Immune	 Hotspot	 =	 22.64,	IHC4+Immune-
Cancer	Hotspot	=	22.96,	IHC4+Cancer	Hotspot	=	23.38,	RS	=	23.53,	ROR	29.18).		
	
	
Discussion	
In	 this	 study,	 we	 aimed	 to	 establish	 the	 prognostic	 value	 of	 immune	 scores	 for	
recurrence	in	ER+	breast	cancer	patients	treated	with	anastrozole	or	tamoxifen.	While	immune	
response	and	 immunotherapy	 for	ER-	diseases	have	been	under	 the	 spotlight,	 correlation	of	
TILs	with	outcomes	 in	 ER+	disease	 is	 less	 clear	 (16),	with	many	 studies	 reporting	 the	 lack	of	
significant	prognostic	 association	 (11,	15,	26,	27).	 In	 line	with	 these	 reports,	we	did	not	 find	
prognostic	value	in	immune	abundance	scores	that	only	account	for	the	amount	of	TILs	in	the	
entire	histology	section	or	in	specific	tumor	regions	including	intra-tumor,	adjacent-tumor,	and	
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distal-tumor,	as	scored	by	digital	histology	slide	image	analysis.	In	contrast,	our	immune	scores	
based	 on	 the	 spatial	 heterogeneity	 of	 TILs	 were	 highly	 prognostic,	 particularly	 for	 late	
recurrence	 after	 5	 years	 of	 endocrine	 therapy.	 This	 suggests	 a	 lasting	 memory	 of	 tumor	
immunity	 on	 disease	 progression	 and	 evolution	 of	 treatment	 resistance	 in	 ER+	 cancer.	 Such	
spatial	heterogeneity	may	reflect	spatial	distribution	patterns	of	different	immune	cell	subsets.	
Intra-tumor	 heterogeneity	 of	 cancer	 cells	 may	 also	 in	 turn	 influence	 immune	 spatial	
distribution	 through	 cytokine	 secretion	 and	 neoantigen	 presentation.	 While	 the	 biological	
mechanisms	 remain	 to	 be	 investigated,	 our	 finding	 has	 significant	 clinical	 implication,	which	
suggests	that	TILs	have	been	previously	overlooked	in	ER+	diseases	due	to	the	lack	of	in-depth	
analysis	of	TILs	on	the	tissue	spatial	organization	level.	Our	findings	highlight	the	importance	of	
examining	not	 just	cell	abundance	but	also	spatial	patterns	that	can	be	 indicative	of	 immune	
functional	phenotypes	and	disease	prognosis.		
In	contrast	to	our	observation	in	ER-	tumors	(13),	high	Immune-Cancer	Hotspot	score,	
indicating	 increased	 spatial	 clustering	 in	 immune	 and	 cancer	 cells,	 correlated	 with	 poor	
prognosis	 in	 ER+	 breast	 cancer.	 However,	 this	 is	 consistent	 with	 our	 previous	 finding	 that	
immune	 gene	 signature	 was	 associated	 with	 poor	 response	 to	 endocrine	 therapy	 in	 a	
neoadjuvant	 setting	 (28,	 29).	 The	 difference	 may	 be	 due	 to	 immune	 composition	 and	
functionality	in	the	two	subtypes,	and	mechanisms	by	which	immune	response	contributes	to	
hormonal	therapy	resistance	(30,	31).	In	a	recent	study	of	immune	composition	in	7,270	breast	
cancers,	higher	 fraction	of	 T-regulatory	 cells	 and	M2	macrophages	and	 lower	 fraction	of	M1	
macrophages	was	found	in	ER+	compared	with	ER-	cancers	(12).	Therefore,	compared	with	ER-	
subtype,	the	immune	landscape	of	ER+	subtype	is	characterized	by	increased	T-cell	regulation	
and	 macrophage	 polarization	 towards	 pro-tumorigenic	 M2,	 which	 is	 consistent	 with	 our	
results.		
Strengths	 of	 this	 study	 include	 the	 large	 patient	 cohort	 with	 long-term	 follow-up	
systematically	 collected	 in	 a	 well-documented	 clinical	 trial,	 well-characterized	 samples	 that	
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enables	 a	 direct	 comparison	 with	 established	 biomarkers,	 and	 fully	 automated	 and	
reproducible	methods	for	immune	scoring.	These	allowed	us	to	evaluate	quantitative	immune	
scoring	 based	 entirely	 on	 H&E-stained	 tumor	 slides,	 which	 are	 readily	 generated	 as	 part	 of	
clinical	 routine.	 Comparison	 of	 the	 automated	 immune	 scores	 with	 a	 pathologist’s	 score	
following	 recommendations	 for	 TIL	 evaluation	 in	 breast	 cancer	 (24)	 in	 a	 subset	 of	 samples	
showed	a	weak	correlation	overall.	This	is,	however,	unsurprising	when	one	considers	that	the	
automated	scores	 include	regions	of	the	tumor	that	are	excluded	on	pathological	evaluation.	
Indeed,	 the	 latter	 includes	 stromal	 TILs	 only,	which	 are	 assessed	 as	percentage	 surface	 area	
that	 is	 inflammatory	as	opposed	to	fibroblastic	 (25).	 In	contrast,	 the	automated	scores	count	
either	the	absolute	number	of	lymphocytes	in	relation	to	cancer	cells,	or	the	frequency	of	(co-
)clustering	 of	 immune	 and	 cancer	 cells.	 Thus,	 the	 information	 gleaned	 from	 these	methods	
potentially	provides	different	biological	 information	about	the	 interaction	between	these	cell	
types,	and,	as	demonstrated	herein,	can	provide	valuable	prognostic	information.	Developing	a	
histology-based	 test	 as	 such	 thus	 has	 the	 advantages	 of	 cost	 effectiveness	 and	 general	
applicability.	 The	prognostic	 value	 of	 immune	 scores	 for	 late	 recurrence	 is	 similar	 to	 that	 of	
IHC4	and	RS	which	is	the	most	widely	used	test	for	residual	risk	of	recurrence	following	surgery	
and	 endocrine.	 Although	 they	 did	 not	 add	 prognostic	 value	 to	 CTS,	 in	 almost	 all	 occasions	
immune	 scores	 add	prognostic	 information	 to	 the	 individual	 components	 that	make	up	CTS,	
including	node	status,	size,	grade,	age	and	treatment.	Since	CTS	was	developed	and	optimized	
using	TransATAC	samples	(4),	the	independent	prognostic	value	of	immune	scores	remains	to	
be	validated	in	further	endocrine	adjuvant	therapy	studies	with	homogeneous	treatments	such	
as	 POETIC	 (32).	 In	 addition,	 the	 strong	 prognostic	 value	 of	 CTS	 and	 ROR	 could	 be	 partly	
explained	 by	 the	 use	 of	 tumor	 size	 in	 their	 calculation,	 which	 is	 a	 highly	 prognostic	 factor.	
Furthermore,	 IHC4	 combined	with	 immune	 score	 is	 statistically	 significantly	more	prognostic	
than	 RS,	 particularly	 for	 late	 recurrence.	 The	 clinical	 utility	 of	 IHC4+	 immune	 scores	 as	 a	
combined	histology-based	test	is	well	worth	exploring.			
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Weaknesses	of	our	study	include	the	use	of	a	single	histology	slide	per	tumor	such	that	
intra-tumor	 heterogeneity	 cannot	 be	 fully	 addressed,	 and	 the	 lack	 of	 immune	markers	 that	
may	provide	further	insights	for	immune	functions	in	ER+	disease	and	better	predictors	due	to	
little	 residual	 tissue	 available.	 In	 addition,	 whether	 our	 methods	 can	 sufficiently	 address	
challenges	 arising	 from	 variability	 in	 factors	 including	 fixation,	 staining,	 and	 acquisition	 in	 a	
clinical	 setting,	 need	 to	 be	 evaluated	 before	 implementation.	 Our	 results	 also	 only	 apply	 to	
women	who	are	chemotherapy-free.	
Furthermore,	our	study	also	provides	relevant	information	for	new	treatment	strategy	
in	 the	 high-risk	 ER+	 population	 identified	 by	 immune	 scores.	 Our	 findings	 support	 different	
immunosuppressive	mechanisms	in	the	ER+	and	ER-subtypes,	and	in	light	of	these	results	call	
for	 the	development	of	novel	 cancer	 therapeutics	 targeting	 the	pathways	 that	 reverse	 these	
mechanisms	specifically	 for	ER+	disease.	This	may	also	help	explain	why	anti-PD1	checkpoint	
inhibition,	 despite	demonstrating	 activity	 as	monotherapy	 in	 early	 phase	 trials	 in	 ER+	breast	
cancer,	 had	 low	 response	 rates	 compared	 with	 triple-negative	 breast	 cancer	 and	 highly	
variable	 among	 trials	 (33,	 34).	 Further,	 we	 speculate	 that	 immune	 scores	may	 be	 useful	 as	
predictive	biomarkers	for	immunotherapy,	given	the	limited	clinical	utility	of	PDL1	expression	
in	guiding	patient	selection	(35).		
In	summary,	enabled	by	fully	automated	image	analysis	of	histology	sections,	our	study	
provided	 an	 additional	 dimension	 to	 the	 analysis	 of	 immune	 functional	 phenotype	 in	 breast	
cancer.	 Spatial	 data	 provided	 by	 histology,	 once	 quantitatively	 analyzed,	 will	 aid	 the	
identification	 of	 clinically	 relevant	 features,	 potentially	 yielding	 predictions	 more	 powerful	
than	measurements	of	cell	abundance	that	ignore	the	spatial	context.	
	
	
Funding	
16		
This	 work	 was	 supported	 by	 the	 Royal	 Marsden	 National	 Institutes	 of	 Health	 Biomedical	
Research	Centre	grant	A105.	MD	and	YY	acknowledge	support	by	the	Royal	Marsden	National	
Institutes	of	Health	Biomedical	Research	Centre.	MD	acknowledges	a	Breast	Cancer	Now	grant	
(CTR-Q4-Y1).	JC	and	IS	acknowledge	a	CRUK	grant	(C569/A16891).	YY	acknowledges	support	by	
CRUK	(C45982/A21808)	and	Wellcome	Trust	(105104/Z/14/Z).	
	
Notes	
The	funder	had	no	role	in	the	design	of	the	study;	the	collection,	analysis,	and	interpretation	of	
the	 data;	 the	 writing	 of	 the	 manuscript;	 and	 the	 decision	 to	 submit	 the	 manuscript	 for	
publication.		
Acknowledgement	 and	disclosure:	We	 thank	Andrew	Dodson	and	Daniel	Nava	Rodrigues	 for	
technical	and	pathological	support.	M.	Dowsett	has	received	commercial	research	grants	and	
speakers	bureau	honoraria	from	AstraZeneca.	
Author	contribution:	MD	and	YY	designed	the	experiments.	AH,	 IS,	KN	and	JC	performed	the	
analyses.	AH,	IS	and	YY	wrote	the	manuscript.	All	authors	have	approved	the	manuscript.		
	 	
17		
References	
1.	 Dowsett	M,	Goldhirsch	A,	Hayes	DF,	Senn	HJ,	Wood	W,	Viale	G.	International	Web-
based	consultation	on	priorities	for	translational	breast	cancer	research.	Breast	cancer	
research	:	BCR.	2007;9(6):R81.	
2.	 Paik	S,	Shak	S,	Tang	G,	Kim	C,	Baker	J,	Cronin	M,	et	al.	A	multigene	assay	to	predict	
recurrence	of	tamoxifen-treated,	node-negative	breast	cancer.	The	New	England	journal	of	
medicine.	2004;351(27):2817-26.	
3.	 Nielsen	TO,	Parker	JS,	Leung	S,	Voduc	D,	Ebbert	M,	Vickery	T,	et	al.	A	comparison	of	
PAM50	intrinsic	subtyping	with	immunohistochemistry	and	clinical	prognostic	factors	in	
tamoxifen-treated	estrogen	receptor-positive	breast	cancer.	Clinical	cancer	research	:	an	
official	journal	of	the	American	Association	for	Cancer	Research.	2010;16(21):5222-32.	
4.	 Cuzick	J,	Dowsett	M,	Pineda	S,	Wale	C,	Salter	J,	Quinn	E,	et	al.	Prognostic	value	of	a	
combined	estrogen	receptor,	progesterone	receptor,	Ki-67,	and	human	epidermal	growth	
factor	receptor	2	immunohistochemical	score	and	comparison	with	the	Genomic	Health	
recurrence	score	in	early	breast	cancer.	Journal	of	clinical	oncology	:	official	journal	of	the	
American	Society	of	Clinical	Oncology.	2011;29(32):4273-8.	
5.	 Sestak	I,	Dowsett	M,	Zabaglo	L,	Lopez-Knowles	E,	Ferree	S,	Cowens	JW,	et	al.	Factors	
predicting	late	recurrence	for	estrogen	receptor-positive	breast	cancer.	Journal	of	the	National	
Cancer	Institute.	2013;105(19):1504-11.	
6.	 Sestak	I,	Dowsett	M,	Ferree	S,	Baehner	FL,	Cuzick	J.	Retrospective	analysis	of	molecular	
scores	for	the	prediction	of	distant	recurrence	according	to	baseline	risk	factors.	Breast	cancer	
research	and	treatment.	2016;159(1):71-8.	
7.	 Savas	P,	Salgado	R,	Denkert	C,	Sotiriou	C,	Darcy	PK,	Smyth	MJ,	et	al.	Clinical	relevance	
of	host	immunity	in	breast	cancer:	from	TILs	to	the	clinic.	Nature	Reviews	Clinical	Oncology.	
2016;13(4):228-41.	
8.	 Denkert	C,	von	Minckwitz	G,	Brase	JC,	Sinn	BV,	Gade	S,	Kronenwett	R,	et	al.	Tumor-
Infiltrating	Lymphocytes	and	Response	to	Neoadjuvant	Chemotherapy	With	or	Without	
Carboplatin	in	Human	Epidermal	Growth	Factor	Receptor	2–Positive	and	Triple-Negative	
Primary	Breast	Cancers.	Journal	of	Clinical	Oncology	2015;33	983-91.	
9.	 Denkert	C,	Loibl	S,	Noske	A,	Roller	M,	Müller	BM,	Komor	M,	et	al.	Tumor-associated	
lymphocytes	as	an	independent	predictor	of	response	to	neoadjuvant	chemotherapy	in	breast	
cancer.	Journal	of	clinical	oncology	:	official	journal	of	the	American	Society	of	Clinical	
Oncology.	2010;28:105-13.	
10.	 Gu-Trantien	C,	Loi	S,	Garaud	S,	Equeter	C,	Libin	M,	de	Wind	A,	et	al.	CD4(+)	follicular	
helper	T	cell	infiltration	predicts	breast	cancer	survival.	The	Journal	of	clinical	investigation.	
2013;123:2873-92.	Epub	2013/06/20.	
11.	 Loi	S,	Sirtaine	N,	Piette	F,	Salgado	R,	Viale	G,	Van	Eenoo	F,	et	al.	Prognostic	and	
predictive	value	of	tumor-infiltrating	lymphocytes	in	a	phase	III	randomized	adjuvant	breast	
cancer	trial	in	node-positive	breast	cancer	comparing	the	addition	of	docetaxel	to	doxorubicin	
with	doxorubicin-based	chemotherapy:	BIG	02-98.	Journal	of	clinical	oncology	:	official	journal	
of	the	American	Society	of	Clinical	Oncology.	2013;31:860-7.	Epub	2013/01/24.	
12.	 Bense	RD,	Sotiriou	C,	Piccart-Gebhart	MJ,	Haanen	JB,	van	Vugt	MA,	de	Vries	EG,	et	al.	
Relevance	of	Tumor-Infiltrating	Immune	Cell	Composition	and	Functionality	for	Disease	
Outcome	in	Breast	Cancer.	Journal	of	the	National	Cancer	Institute.	2017;109(1).	
13.	 Nawaz	S,	Heindl	A,	Koelble	K,	Yuan	Y.	Beyond	immune	density:	critical	role	of	spatial	
heterogeneity	in	estrogen	receptor-negative	breast	cancer.	Modern	pathology	:	an	official	
journal	of	the	United	States	and	Canadian	Academy	of	Pathology,	Inc.	2015.	
14.	 Dieci	MV,	Criscitiello	C,	Goubar	A,	Viale	G,	Conte	P,	Guarneri	V,	et	al.	Prognostic	value	
of	tumor-infiltrating	lymphocytes	on	residual	disease	after	primary	chemotherapy	for	triple-
18		
negative	breast	cancer:	a	retrospective	multicenter	study.	Annals	of	oncology	:	official	journal	
of	the	European	Society	for	Medical	Oncology	/	ESMO.	2014;25:611-8.	Epub	2014/01/10.	
15.	 Loi	S,	Michiels	S,	Salgado	R,	Sirtaine	N,	Jose	V,	Fumagalli	D,	et	al.	Tumor	infiltrating	
lymphocytes	are	prognostic	in	triple	negative	breast	cancer	and	predictive	for	trastuzumab	
benefit	in	early	breast	cancer:	Results	from	the	FinHER	trial.	Annals	of	Oncology.	
2014;25:1544-50.	
16.	 Luen	S,	Virassamy	B,	Savas	P,	Salgado	R,	Loi	S.	The	genomic	landscape	of	breast	cancer	
and	its	interaction	with	host	immunity.	Breast.	2016;29:241-50.	
17.	 Yuan	Y,	Failmezger	H,	Rueda	OM,	Ali	HR,	Graf	S,	Chin	S-FF,	et	al.	Quantitative	image	
analysis	of	cellular	heterogeneity	in	breast	tumors	complements	genomic	profiling.	Science	
translational	medicine.	2012;4:157ra43.	Epub	2012/11/24.	
18.	 Yuan	Y.	Modelling	the	Spatial	Heterogeneity	and	Molecular	Correlates	of	Lymphocytic	
Infiltration	in	Triple-Negative	Breast	Cancer.	Journal	of	the	Royal	Society:	Interface.	2015;12.	
19.	 Yuan	Y.	Spatial	Heterogeneity	in	the	Tumor	Microenvironment.	Cold	Spring	Harbor	
perspectives	in	medicine.	2016;6(8).	
20.	 Demaria	S,	Kawashima	N,	Yang	AM,	Devitt	ML,	Babb	JS,	Allison	JP,	et	al.	Immune-
mediated	inhibition	of	metastases	after	treatment	with	local	radiation	and	CTLA-4	blockade	in	
a	mouse	model	of	breast	cancer.	Clinical	cancer	research	:	an	official	journal	of	the	American	
Association	for	Cancer	Research.	2005;11:728-34.	Epub	2005/02/11.	
21.	 Fridman	WH,	Pages	F,	Sautes-Fridman	C,	Galon	J.	The	immune	contexture	in	human	
tumours:	impact	on	clinical	outcome.	Nature	reviews	Cancer.	2012;12:298-306.	Epub	
2012/03/16.	
22.	 Gentles	AJ,	Newman	AM,	Liu	CL,	Bratman	SV,	Feng	W,	Kim	D,	et	al.	The	prognostic	
landscape	of	genes	and	infiltrating	immune	cells	across	human	cancers.	Nature	medicine.	
2015.	
23.	 Dowsett	M,	Cuzick	J,	Wale	C,	Forbes	J,	Mallon	EA,	Salter	J,	et	al.	Prediction	of	risk	of	
distant	recurrence	using	the	21-gene	recurrence	score	in	node-negative	and	node-positive	
postmenopausal	patients	with	breast	cancer	treated	with	anastrozole	or	tamoxifen:	a	
TransATAC	study.	Journal	of	clinical	oncology	:	official	journal	of	the	American	Society	of	
Clinical	Oncology.	2010;28(11):1829-34.	
24.	 Salgado	R,	Denkert	C,	Demaria	S,	Sirtaine	N,	Klauschen	F,	Pruneri	G,	et	al.	The	
evaluation	of	tumor-infiltrating	lymphocytes	(TILs)	in	breast	cancer:	recommendations	by	an	
International	TILs	Working	Group	2014.	Annals	of	oncology	:	official	journal	of	the	European	
Society	for	Medical	Oncology	/	ESMO.	2014:mdu450-.	
25.	 Curtis	C,	Shah	SP,	Chin	SF,	Turashvili	G,	Rueda	OM,	Dunning	MJ,	et	al.	The	genomic	and	
transcriptomic	architecture	of	2,000	breast	tumours	reveals	novel	subgroups.	Nature.	
2012;486:346-52.	Epub	2012/04/24.	
26.	 Dieci	MV,	Criscitiello	C,	Goubar	a,	Viale	G,	Conte	P,	Guarneri	V,	et	al.	Prognostic	value	
of	tumor-infiltrating	lymphocytes	on	residual	disease	after	primary	chemotherapy	for	triple-
negative	breast	cancer:	a	retrospective	multicenter	study.	Annals	of	oncology	:	official	journal	
of	the	European	Society	for	Medical	Oncology	/	ESMO.	2014;25:611-8.	
27.	 Ali	HR,	Provenzano	E,	Dawson	SJ,	Blows	FM,	Liu	B,	Shah	M,	et	al.	Association	between	
CD8+T-cell	infiltration	and	breast	cancer	survival	in	12	439	patients.	Annals	of	Oncology.	
2014;25(8):1536-43.	
28.	 Dunbier	AK,	Ghazoui	Z,	Anderson	H,	Salter	J,	Nerurkar	A,	Osin	P,	et	al.	Molecular	
profiling	of	aromatase	inhibitor-treated	post-menopausal	breast	tumors	identifies	immune-
related	correlates	of	resistance.	Clinical	cancer	research	:	an	official	journal	of	the	American	
Association	for	Cancer	Research.	2013.	Epub	2013/03/16.	
29.	 Gao	Q,	Patani	N,	Dunbier	AK,	Ghazoui	Z,	Zvelebil	M,	Martin	LA,	et	al.	Effect	of	
aromatase	inhibition	on	functional	gene	modules	in	estrogen	receptor-positive	breast	cancer	
19		
and	their	relationship	with	antiproliferative	response.	Clinical	cancer	research	:	an	official	
journal	of	the	American	Association	for	Cancer	Research.	2014;20(9):2485-94.	
30.	 Wei	C,	Cao	Y,	Yang	X,	Zheng	Z,	Guan	K,	Wang	Q,	et	al.	Elevated	expression	of	TANK-
binding	kinase	1	enhances	tamoxifen	resistance	in	breast	cancer.	Proceedings	of	the	National	
Academy	of	Sciences	of	the	United	States	of	America.	2014;111(5):E601-10.	
31.	 Jansen	MP,	Foekens	JA,	van	Staveren	IL,	Dirkzwager-Kiel	MM,	Ritstier	K,	Look	MP,	et	al.	
Molecular	classification	of	tamoxifen-resistant	breast	carcinomas	by	gene	expression	profiling.	
Journal	of	clinical	oncology	:	official	journal	of	the	American	Society	of	Clinical	Oncology.	
2005;23(4):732-40.	
32.	 Dowsett	M,	Smith	I,	Robertson	J,	Robison	L,	Pinhel	I,	Johnson	L,	et	al.	Endocrine	
therapy,	new	biologicals,	and	new	study	designs	for	presurgical	studies	in	breast	cancer.	
Journal	of	the	National	Cancer	Institute	-	Monographs.	2011:120-3.	
33.	 Dirix	LY,	Takacs	I,	Nikolinakos	P,	Jerusalem	G,	Arkenau	HT,	Hamilton	EP,	et	al.	
Avelumab	(MSB0010718C),	an	anti-PD-L1	antibody,	in	patients	with	locally	advanced	or	
metastatic	breast	cancer:	A	phase	1b	JAVELIN	solid	tumor	trial.	Cancer	research.	2016;76.	
34.	 Rugo	HS,	Delord	JP,	Im	SA,	Ott	PA,	Piha-Paul	SA,	Bedard	PL,	et	al.	Preliminary	efficacy	
and	safety	of	pembrolizumab	(MK-3475)	in	patients	with	PD-L1	positive,	estrogen	receptor-
positive	(ER+)/HER2-negative	advanced	breast	cancer	enrolled	in	KEYNOTE-028.	Cancer	
research.	2016;76.	
35.	 Patel	SP,	Kurzrock	R.	PD-L1	Expression	as	a	Predictive	Biomarker	in	Cancer	
Immunotherapy.	Molecular	cancer	therapeutics.	2015;14(4):847-56.	
	
	
	 	
20		
Tables			
Table	1.	Immune	scores	and	prognostic	scores*	
Type	and	Name	 Definition	 Reference	
Immune	abundance	scores	(based	on	
H&E)	
	 	
LI:	Lymphocytic	Infiltrate	 Fraction	of	lymphocytes	in	all	cells.	Cells	were	
identified	using	automated	histology	image	
analysis.		
Yuan	et	al.,	2012	(17)	
ITLR:	Intra-Tumor	Lymphocyte	Ratio		 The	number	of	intra-tumor	lymphocytes	
normalized	by	the	number	of	cancer	cells.		
Intra-tumor	lymphocytes	were	identified	as	the	
cluster	of	lymphocytes	to	be	the	closest	to	
cancer	cells	based	on	their	spatial	proximity	in	
unsupervised	clustering.	
Yuan	et	al.,	2015	(18)	
ATLR:	Adjacent-Tumor	Lymphocyte	
Ratio	
The	number	of	adjacent-to-tumor	lymphocytes	
normalized	by	the	number	of	cancer	cells.	
Adjacent-to-tumor	lymphocytes	were	
identified	as	the	intermediate	cluster	of	
lymphocytes	based	on	their	spatial	proximity	
to	cancer	cells	in	unsupervised	clustering.	
DTLR:	Distal-Tumor	Lymphocyte	
Ratio		
The	number	of	distal-tumor	lymphocytes	
normalized	by	the	number	of	cancer	cells.	
Distal-tumor	lymphocytes	were	identified	as	
the	cluster	of	lymphocytes	to	be	the	furthest	
away	from	cancer	cells	based	on	their	spatial	
proximity	in	unsupervised	clustering.	
Immune	spatial	scores	(H&E)	 	 	
Cancer	Hotspot	 Fraction	of	tissue	displaying	spatial	clustering	
of	cancer	cells.	Tumor	regions	with	spatial	
clustering	of	cancer	cells	were	identified	using	
Getis-Ord	hotspot	analysis,	which	assigned	
statistical	significance	of	difference	between	
observed	local	cancer	cell	density	and	global	
mean.	
Nawaz	et	al.,	2015	
(13)	
Immune	Hotspot	 Fraction	of	tissue	displaying	spatial	clustering	
of	immune	cells.	Tumor	regions	with	spatial	
clustering	of	immune	cells	were	identified	in	a	
similar	way	as	cancer	hotspots.	
Immune-Cancer	Hotspot	 Fraction	of	tissue	displaying	spatial	clustering	
of	immune	and	cancer	cells	simultaneously,	in	
other	words,	tumor	regions	that	are	both	
immune	hotspots	and	cancer	hotspots.		
Prognostic	scores	 	 	
IHC4	(IHC)	 Immunohistochemistry-based	score	as	a	
combination	of	ER,	PgR,	HER2,	Ki67	expression,	
previously	derived	using	TransATAC	samples.		
Cuzick	et	al.,	2011	(4)	
CTS	(clinical)	 Clinical	treatment	score	that	consider	node	
status,	size,	grade,	age	and	treatment,	
previously	derived	using	TransATAC	samples.	
Cuzick	et	al.,	2011	(4)	
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RS	(Molecular)	 Oncotype	DX	21-gene	recurrence	score	based	
on	RNA	expression	of	21	prespecified	
Oncotype	DX	genes.		
Paik	et	al.,	2004	(2)	
ROR	(Molecular)	 PAM50	risk	of	recurrence	score	that	combine	
molecular	signatures	with	clinical	information	
on	tumor	size.	
Nielsen	et	al.,	2010	(3)	
*Unless	specified	otherwise,	the	scores	were	predefined	for	validation	in	external	cohorts.		
H&E:	hematoxylin	&	eosin,	IHC:	immunohistochemistry.		
	
22		
Table	2.	Correlations	among	immune	scores	and	clinical	variables	in	TransATAC	and	METABRIC*		
Dataset	/	variable	 ITL	 ATL	 DTL	 LI	
Cancer	
Hotspot	
Immune	
Hotspot	
Immune-Cancer	
Hotspot	
Age	 Grade	 Node	 Size	 Treatment	
TransATAC	 	 	           
ITL	 --	 --	 -- -- -- -- -- -- -- -- -- -- 
ATL	 -0.317	 --	 --	 -- -- -- -- -- -- -- -- -- 
DTL	 -0.888	 -0.154	 --	 --	 -- -- -- -- -- -- -- -- 
LI	 -0.01	 0.381	 -0.174	 --	 --	 -- -- -- -- -- -- -- 
Cancer	Hotspot	 -0.422	 0.309	 0.289	 0.167	 --	 --	 -- -- -- -- -- -- 
Immune	Hotspot	 -0.395	 0.409	 0.213	 0.476	 0.796	 --	 --	 -- -- -- -- -- 
Immune-Cancer	Hotspot	 -0.408	 0.203	 0.327	 0.341	 0.502	 0.75	 --	 --	 -- -- -- -- 
Age	 0.01	 0.018	 -0.019	 -0.036	 0.145	 0.077	 0.033	 --	 --	 -- -- -- 
Grade	 -0.168	 0.126	 0.114	 0.144	 0.268	 0.287	 0.243	 0.128	 --	 --	 -- -- 
node	 0.007	 0.212	 -0.018	 0.213	 0.096	 0.096	 0.107	 0.188	 0.099	 --	 --	 -- 
Size	 0.021	 -0.012	 -0.016	 -0.051	 0.231	 0.194	 0.155	 0.247	 0.171	 0.322	 --	 --	
Treatment	 0.028	 -0.03	 -0.014	 0.044	 -0.023	 0.021	 0.048	 -0.002	 -0.014	 0.007	 0.024	 --	
METABRIC	 	 	 	 	 	 	 	 	 	 	 	 	
ITL	 --	 --	 --	 --	 --	 --	 --	 --	 --	 --	 --	 --	
ATL	 -0.276	 --	 --	 --	 --	 --	 --	 --	 --	 --	 --	 --	
DTL	 -0.83	 -0.306	 --	 --	 --	 --	 --	 --	 --	 --	 --	 --	
LI	 0.077	 0.199	 -0.191	 --	 --	 --	 --	 --	 --	 --	 --	 --	
Cancer	Hotspot	 -0.331	 0.035	 0.307	 0.062	 --	 --	 --	 --	 --	 --	 --	 --	
Immune	Hotspot	 -0.319	 0.16	 0.223	 0.29	 0.849	 --	 --	 --	 --	 --	 --	 --	
Immune-Cancer	Hotspot	 -0.253	 0.051	 0.221	 0.152	 0.796	 0.824	 --	 --	 --	 --	 --	 --	
*ITLR:	Intra-Tumor	Lymphocyte	Ratio,	ATLR:	Adjacent-to-Tumor	Lymphocyte	Ratio,	DTLRL:	Distal-To-Tumor	Lymphocyte	Ratio,	LI:	Lymphocytic	Infiltration.	
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Table	 3.	 Comparison	of	 prognostic	 value	of	 immune	 scores,	 classical	 clinical	 variables,	 and	
prognostic	 scores	 tests	 in	 univariate	 and	 multivariate	 analyses	 adjusted	 for	 nodal	 status,	
grade,	size,	age	and	treatment	(all	CTS	components).		
Group	 n	
No.	
of	
Rec
urre
nce
s	
Univariate	 Multivariate*	
Immune	Hotspot	 Cancer	Hotspot	 Immune-Cancer	Hotspot	 Immune	Hotspot	 Cancer	Hotspot	
Immune-Cancer	
Hotspot	
HR(9
5%CI)	
LR
-
χ2	
P†	 HR(95%CI)	
LR-
χ2	 P†	
HR(9
5%CI)	
LR-
χ2	 P†	
HR(9
5%CI)	
LR
-
χ2	
P†	 HR(95%CI)	
LR
-
χ2	
P†	 HR(95%CI)	
LR
-χ2	 P†	
All	
patient
s	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
0-5	
years	
11
78	
103	 1.23	
(1.06-
1.43)	
6.
24	
0.
01	
1.31	
(1.12-
1.53)	
9.8
3	
0.0
02	
1.30	
(1.14-
1.49)	
11.
46	
<0
.0
01	
1.13	
(0.97-
1.32)	
4.
56	
0.
03	
1.20	
(1.02-
1.41)	
2.
36	
0.
12	
1.20	
(1.05-
1.38)	
5.
85	
0.
01
56	
5-10	
years	
10
19	
113	 1.26	
(1.09-
1.47)	
7.
89	
0.
00
5	
1.30	
(1.11-
1.52)	
9.3
4	
0.0
02	
1.24	
(1.05-
1.47)	
5.4
5	
0.
01	
1.16	
(1.00-
1.35)	
3.
61	
0.
05	
1.21	
(1.03-
1.42)	
5.
11	
0.
02	
1.14	
(0.97-
1.35)	
2.
27	
0.
13	
0-10	
years	
11
78	
216	 1.25	
(1.23-
1.39)	
14
.0
6	
<0
.0
01	
1.30	
(1.17-
1.46)	
19.
16	
<0.
00
1	
1.28	
(1.15-
1.42)	
16.
72	
<0
.0
00
1	
1.15	
(1.03-
1.28)	
5.
91	
0.
01	
1.20	
(1.08-
1.35)	
9.
59	
0.
00
2	
1.17	
(1.06-
1.30)	
7.
77	
0.
00
53	
HER2-
negativ
e	
patient
s	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
0-5	
years	
10
37	
78	 1.23	
(1.04-
1.46)	
4.
63	
0.
03	
1.33	
(1.11-
1.59)	
8.5
0	
0.0
03	
1.26	
(1.06-
1.49)	
5.5
6	
0.
01	
1.12	
(0.94-
1.34)	
1.
49	
0.
22	
1.21	
(1.01-
1.46)	
3.
78	
0.
05	
1.14	
(0.96-
1.36)	
2.
00	
0.
16	
5-10	
years	
90
9	
102	 1.33	
(1.14-
1.54)	
10
.9	
0.
00
1	
1.39	
(1.18-
1.62)	
13.
77	
<0.
00
1	
1.33	
(1.12-
1.57)	
8.6
3	
0.
00
3	
1.23	
(1.06-
1.42)	
6.
31	
0.
01	
1.30	
(1.11-
1.53)	
9.
09	
0.
00
2	
1.22	
(1.04-
1.44)	
4.
95	
0.
02
6	
0-10	
years	
10
37	
180	 1.28	
(1.15-
1.44)	
15
.1
0	
<0
.0
01	
1.36	
(1.21-
1.53)	
22.
17	
<0.
00
1	
1.29	
(1.14-
1.45)	
13.
98	
<0
.0
01	
1.18	
(1.05-
1.32)	
7.
01	
0.
00
8	
1.26	
(1.12-
1.42)	
12
.4
9	
<0
.0
01	
1.18	
(1.05-
1.32)	
6.
33	
0.
01
2	
*Adjusted	for	node,	grade,	tumor	size,	age,	treatment.	CI=confidence	interval;	HR=hazard	ratio;	CTS=clinical	treatment	score	
†	Likelihood	Ratio	χ	2,	P-value	two-sided	[Please	name	the	statistical	test	used	to	calculate	the	P	values	and	say	if	it	was	two-
sided.]	
	
Table	4.	Additional	prognostic	value	of	immune	spatial	scores	to	IHC4	and	RS	in	all	patients	
and	Her2-	subgroup.		
All	patients	
Immune	Spatial	Score	[Correct?]	
0-10	(N=963)	 5-10	(N=824)	
HR	(95%CI)	 ∆LR-χ2	 P*	 HR	(95%CI)	 ∆LR-χ2	 P*	
	 	 	 	 	 	 	
Cancer	Hotspot	to	IHC4	 1.22	(1.08-1.37)	 9.72	 0.002	 1.24	(1.04-1.47)	 5.57	 0.02	
Cancer	Hotspot	to	RS	 1.25	(1.11-1.41)	 12.46	 <0.001	 1.27	(1.07-1.49)	 6.97	 0.008	
Immune	Hotspot	to	IHC4	 1.13	(1.01-1.27)	 3.93	 0.05	 1.19	(1.02-1.40)	 4.10	 0.04	
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Immune	Hotspot	to	RS	 1.14	(1.02-1.28)	 4.50	 0.03	 1.21	(1.03-1.42)	 4.71	 0.03	
Immune-Cancer	Hotspot	to	
IHC4	
1.17	(1.04-1.31)	 5.87	 0.02	 NS	 NS	 NS	
Immune-Cancer	Hotspot	to	
RS	
1.15	(1.02-1.29)	 4.76	 0.03	 NS	 NS	 NS	
Her2	subgroup	
0-10	(N=848)	 5-10	(N=733)	
HR	(95%CI)	 ∆LR-χ2	 P*	 HR	(95%CI)	 ∆LR-χ2	 P*	
Cancer	Hotspot	to	IHC4	 1.26	(1.11-1.43)	 11.73	 <0.001	 1.32	(1.12-1.57)	 9.31	 0.002	
Cancer	Hotspot	to	RS	 1.29	(1.14-1.46)	 14.28	 <0.001	 1.37	(1.16-1.61)	 11.82	 <0.001	
Immune	Hotspot	to	IHC4	 1.14	(1.02-1.30)	 4.56	 0.03	 1.23	(1.05-1.44)	 5.71	 0.02	
Immune	Hotspot	to	RS	 1.15	(1.02-1.30)	 4.84	 0.03	 1.26	(1.08-1.47)	 7.12	 0.008	
Immune-Cancer	Hotspot	to	
IHC4	
1.17	(1.04-1.33)	 5.64	 0.02	 1.24	(1.04-1.48)	 4.95	 0.03	
Immune-Cancer	Hotspot	to	
RS	
1.13	(0.99-1.29)	 3.22	 0.07	 1.23	(1.03-1.47)	 4.69	 0.03	
*	 Likelihood	 Ratio	 χ	 2,	 P-value	 two-sided;	 CI=confidence	 interval;	 HR=hazard	 ratio;	
RS=Oncotype	DX	21-gene	recurrence	score.	
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Figure	legends	
Figure	 1.	 Consort	 diagram	 for	 the	 availability	 of	 samples	 for	 analysis	 from	 the	 ATAC	
(Arimidex,	 Tamoxifen	 Alone	 or	 Combined)	 trial.	 ER,	 estrogen	 receptor;	 IHC,	
immunohistochemistry;	 PgR,	 progesterone	 receptor;	 ROR,	 Risk	 of	 Recurrence	 score;	 RS,	
recurrence	score.		
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available 
N=963 
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Figure	2.	Illustration	of	the	pipeline	for	identifying	spatial	hotspots	with	visual	examples,	and	
the	Kaplan-Meier	estimates	for	10-year	recurrence	according	to	immune	spatial	scores	in	the	
validation	set,	split	into	two	groups	using	cutoffs	selected	in	the	training	set.	A)	An	example	
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of	TransATAC	H&E	image	and	corresponding	map	of	identified	cancer	and	immune	cells.	Scale	
bar	 illustrates	2.5mm.	B-D)	Visual	 examples	of	hotspots	 and	Kaplan-Meier	 curves	 illustrating	
survival	 associations	 with	 immune	 spatial	 scores.	 Scale	 bar	 illustrates	 35μm.	 Kaplan-Meier	
curves	were	calculated	and	tested	for	equality	using	the	log-rank	test.	The	numbers	of	patients	
at	 risk	 in	 each	 group	 at	 various	 time	 points	 are	 given	 below	 each	 graph.	 All	 statistical	 tests	
were	two-sided.	HR:	hazard	ratio	(95%	confidence	interval).		
	
Figure	3.	Barplots	of	likelihood	scores	for	immune	spatial	and	prognostic	scores	as	well	as	
combination	of	IHC4	and	each	immune	spatial	score	(IHC4+I)	for	0-10	and	5-10	year	time	
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window	in	A)	overall	population	and	B)	HER2-	population.	Kaplan-Meier	curves	were	
calculated	and	tested	for	equality	using	the	log-rank	test.	The	numbers	of	patients	at	risk	in	
each	group	at	various	time	points	are	given	below	each	graph.	All	statistical	tests	were	two-
sided.	
	
	
